BioCentury
ARTICLE | Clinical News

AGIX begins AGI-1067 Phase IIb

December 20, 2001 8:00 AM UTC

AtheroGenics (AGIX) began the CART-2 Phase IIb study of AGI-1067 to treat restenosis and atherosclerosis. In the 500-patient Canadian study, patients will receive 280 mg of the product for 12 months. ...